CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Hepatitis B Vaccine (Recombinant)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02055365
NCT02055365N/ACompleted
CompareCT.gov

Effects of Persistent Innate Immune Activation on Vaccine Efficacy Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers

Rockefeller University·interventional·Posted Feb 5, 2014·Updated May 7, 2018

In Brief

A clinical study evaluating Hepatitis B Vaccine (Recombinant) for Hepatitis B. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Vaccines have been responsible for preventing millions of deaths and extending the average human lifespan. Effective vaccines stimulate the cells of the immune system to activate genes and associated functions that bring about protective immunity.This study aims to define cellular functions and genes important for the hepatitis B (HBV) vaccine immune response in healthy individuals. The investigators hypothesize that many genes associated with innate and adaptive immune functions are important for an effective HBV vaccine response.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 5, 2014
Enrollment StartFeb 18, 2014
Primary CompletionJan 6, 2015
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.4 years ago

Interventions

Hepatitis B Vaccine (Recombinant)biological

All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).